Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

作     者：Jie Hu Xiao-yu Wei Jin Xiang Pai Peng Feng-li Xu Kang Wu Fei-yang Luo Ai-shun Jin Liang Fang Bei-zhong Liu Kai Wang Ni Tang Ai-Long Huang 

作者机构：Key Laboratory of Molecular Biology for Infectious Diseases(Ministry of Education)Institute for Viral HepatitisDepartment of Infectious DiseasesThe Second Affiliated HospitalChongqing Medical UniversityChongqing 400010PR China Yong-Chuan HospitalChongqing Medical UniversityChongqing 402177PR China Department of ImmunologyCollege of Basic MedicineChongqing Medical UniversityChongqing 400016PR China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2022年第9卷第5期

页      面：1290-1300页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(No.U20A20392) the 111 Project(No.D20028) Open Research Fund Program of the Key Laboratory of Molecular Biology for Infectious Diseases,China(No.CQMU202102 and CQMU202105) The Science and Technology Research Program of Chongqing Municipal Education Commission,China(No.KJZD-M202000401) The Natural Science Foundation Project of Chongqing,China(No.cstc2019jscx-dxwtBX0019) The Emergency Project from the Science&Technology Commission of Chongqing,China(No.cstc2020jscx-fyzx0053 and cstc2020jscx-dxwtB0050) Kuanren Talents Program of the second affiliated hospital of Chongqing Medical University,the Emergency Project for Novel Coronavirus Pneumonia from the Chongqing Medical University,China(No.CQMUNCP0302) China Postdoctoral Science Foundation,China(No.2021M693924) Chongqing Postdoctoral Science Special Foundation,China(No.2010010005216630) 

主　　题：Coronavirus Immune escape Mutation Neutralizing antibodies SARS-CoV-2 Vaccine Viral entry 

摘      要：Coronavirus disease 2019(COVID-19)is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody ***,multiple variants of SARS-CoV-2 have emerged,which may potentially compromise vaccine *** a pseudovirus-based assay,we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 *** also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies(NAbs)elicited by CoronaVac(inactivated vaccine)and ZF2001(RBD-subunit vaccine)against B.1.617 and B.1.1.7 *** results showed that,compared to D614G and B.1.1.7 variants,B.1.617 shows enhanced viral entry and membrane fusion,as well as more resistant to antibody *** findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.